These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

911 related items for PubMed ID: 31285305

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN.
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U, Weber B, Sarr C, Freiwald M.
    BMC Pulm Med; 2021 Jul 21; 21(1):244. PubMed ID: 34289823
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs).
    Joannes A, Voisin T, Morzadec C, Letellier A, Gutierrez FL, Chiforeanu DC, Le Naoures C, Guillot S, De Latour BR, Rouze S, Jaillet M, Crestani B, Wollin L, Jouneau S, Vernhet L.
    Pulm Pharmacol Ther; 2023 Dec 21; 83():102267. PubMed ID: 37972706
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE, Kahn N, Wälscher J, Sarmand N, Polke M, Lars K, Eichinger M, Heussel CP, Palmucci S, Sambataro FM, Sambataro G, Sambataro D, Vancheri C, Kreuter M.
    BMC Pulm Med; 2019 Nov 12; 19(1):213. PubMed ID: 31718637
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
    Gibson CD, Kugler MC, Deshwal H, Munger JS, Condos R.
    Lung; 2020 Aug 12; 198(4):597-608. PubMed ID: 32591895
    [Abstract] [Full Text] [Related]

  • 17. Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.
    Matteson EL, Kelly C, Distler JHW, Hoffmann-Vold AM, Seibold JR, Mittoo S, Dellaripa PF, Aringer M, Pope J, Distler O, James A, Schlenker-Herceg R, Stowasser S, Quaresma M, Flaherty KR, INBUILD Trial Investigators.
    Arthritis Rheumatol; 2022 Jun 12; 74(6):1039-1047. PubMed ID: 35199968
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The dorsal muscle group area at the T12 vertebral level as a risk factor for tolerability of nintedanib in patients with idiopathic pulmonary fibrosis or other progressive fibrosing interstitial lung diseases.
    Ono M, Kobayashi S, Masakazu H, Ishida M, Sato H, Okutomo K, Shirai Y, Takahashi K, Yamada M, Fujino N, Yamanda S, Yanai M.
    Medicine (Baltimore); 2024 Jul 12; 103(28):e38920. PubMed ID: 38996147
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.